The Lavipharm Group in the first half of 2026 presents a significant increase in consolidated sales before claw back and rebate by 24.1%, while EBITDA profits from continuing operations increased by 5.2%.
Specifically, consolidated sales from continuing operations amounted to €38.5 million compared to €31.0 million in the corresponding period of 2025, recording an increase of 24.1%. In particular, sales abroad increased by 35%, sales of prescription medicines in the domestic market increased by 23%, while OTC sales increased by 3%. Consolidated sales, after the deduction of rebates and clawback, amounted to €34.4 million compared to €26.7 million in the corresponding half of 2025, showing an increase of 28.9%. Total adjusted EBITDA profits came to €7.1 million compared to €7.7 million in the first half of 2025, showing a decline of 7.7% due to the extraordinary income of €0.9 million from the sale of the company Pharma Plus that took place in the first half of 2025.
Consolidated profits after taxes amounted to €2.4 million compared to €2.6 million in the first half of 2025. This decrease is also due to the income from the sale of the company Pharma Plus that was recognized in the first half of 2025. It is worth noting that excluding this specific income, net profits from continuing operations increased by 41.3% compared to the first half of 2025.
The Group's net debt, on 30/6/2026, amounted to €37.7 million, increased compared to 31/12/2025 due to the bank financing of the acquisition of DUROGESIC®.
Mr. Vasilis Baloumis, Chief Financial Officer of Lavipharm stated: «The Group's upward trajectory will continue at a faster pace in the second half of 2026. Sales for the period are expected to be significantly higher than those of the first half, both in the domestic market and abroad, where the pace of order execution will increase particularly until the end of the year. It is worth noting that this estimate does not incorporate DUROGESIC®, whose commercial launch is expected to begin in early October, as the licensing procedures have already been completed in the countries with the greatest commercial interest. Finally, it is noted that the figures for the first half have been burdened by an amount of approximately €300 thousand, which concerns payroll-related expenses in order to implement the commercial exploitation of this specific product».